The successful development of an antibody–drug conjugate (ADC) targeting HER2 and the findings of its survival benefit4 have led some to consider refining HER2 expression status and exploring factors related to the prognosis of HER2‐low BC patients. This evidence concerns the gene ERBB2 and breast cancer.